Oncology

Study warns that drug reviewers don't look at long term survival of patients.

Particles protected antigen from premature destruction and prompted the immune system to attack cancer cells.

Age and weight found to play a role in side effects.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses changes in store for the care of cancer patients over the next decade.

Mass spectrometry reveals all proteins that repair damaged cancer DNA.

Targeting gene mutations causes stress that damages cancer cell DNA.

Treating immune-suppressing cells allows for destruction of tumors.

Study finds chronic hepatitis C has a limited impact on mortality unless the patient has other severe comorbidities.

Despite advances in pain management and palliative care, intractable cancer pain remains a significant clinical, social, and financial burden in treating the oncologic population.

Genetically determined telomere length may not influence mortality.

Particulate matter found in 8 lots of Adrucil 50 mg/mL.

Researchers find significant reduction in lung cancer-specific deaths.

Levoleucovorin is for rescue use after high-dose methotrexate therapy in bone cancer.

Cancer rates significantly greater compared with non-infected individuals.

Sandoz has introduced its ready-to-use levoleucovorin injection to the US market.

Highest uninsured rates found in patients with testicular, stomach, and cervical cancers.

BRAF mutations commonly found in melanoma also seen in subset of lung cancer patients.

Introduction of protein to pancreatic cancer cells causes them to revert back to normal.

FDA finds that infusion pump did follow quality system regulations for medical devices that ensure safe use.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses the changing role of specialty pharmacy in cancer treatment.

Taking over-the-counter supplements beyond the recommended amount could increase cancer risk.

Suppression of Wnt signaling pathway shows promise.

Re-engineering antibodies allows them to selectively kill tumors.

Pfizer seeking to expand approved use of Xalkori to patients with ROS1-positive non-small cell lung cancer.

Regulating PD-L1 protein that helps cancer evade immune system suggests new therapeutic approach.

The FDA has awarded Breakthrough Therapy status to crizotinib (Xalkori) for ROS1-positive non-small cell lung cancer.

Researchers determine mechanism for poor survival rates in African American patients with estrogen-receptor positive breast cancer.

Mild exercise found to improve fatigue and depression.